Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Receivables - Net: 2019-2025

Historic Receivables - Net for Legend Biotech (LEGN) over the last 4 years, with Sep 2025 value amounting to $1.2 million.

  • Legend Biotech's Receivables - Net rose 75.32% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 75.32%. This contributed to the annual value of $6.3 million for FY2024, which is 93.72% down from last year.
  • As of Q3 2025, Legend Biotech's Receivables - Net stood at $1.2 million, which was down 95.52% from $27.6 million recorded in Q2 2025.
  • Legend Biotech's 5-year Receivables - Net high stood at $100.0 million for Q4 2023, and its period low was $20,000 during Q3 2023.
  • In the last 3 years, Legend Biotech's Receivables - Net had a median value of $3.3 million in 2024 and averaged $15.2 million.
  • Over the last 5 years, Legend Biotech's Receivables - Net had its largest YoY gain of 111,056.67% in 2023, and its largest YoY loss of 99.89% in 2023.
  • Quarterly analysis of 5 years shows Legend Biotech's Receivables - Net stood at $50.4 million in 2021, then crashed by 99.82% to $90,000 in 2022, then spiked by 111,056.67% to $100.0 million in 2023, then crashed by 93.72% to $6.3 million in 2024, then surged by 75.32% to $1.2 million in 2025.
  • Its Receivables - Net was $1.2 million in Q3 2025, compared to $27.6 million in Q2 2025 and $369,000 in Q1 2025.